A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.

In this study, 19 evaluable patients with epithelial ovarian cancer were treated with amonafide 300 mg/m2 over an hour for 5 consecutive days every 3 weeks. One partial response (5%) was seen. Hematologic toxicity was substantial with grade 3 or 4 toxicity occurring as follows: leukopenia, 10 patients (45%); thrombocytopenia, 6 patients (27%); granulocytopenia, 8 patients (36%). No other unusual or severe toxicity occurred. In view of the low response rate and high toxicity, amonafide does not warrant further investigation in epithelial ovarian cancer.